Voltammetric Behavior of Antileukemia Drug Glivec. Part III: In Situ DNA Oxidative Damage by the Glivec Electrochemical Metabolite

Abstract

Glivec is a relatively small molecule with activity against the protein tyrosine kinase, a protein expressed by all patients with chronic myelogenous leukemia (CML). Based on its activity on CML, glivec is undergoing extensive evaluation of its activity against other types of tumor. As a result, there is an ongoing need for clarification of glivec pharmacokinetics so that issues such as drug-biomolecular complex interactions can be understood.